Search filters

Filters
Clear All

Phase

  • 4
  • 13
  • 7
  • 5
  • 3
  • 35
  • 20
  • 35
  • 34
  • 1

Found 35 Leukemia trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Randomized  Multicenter  Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
18 years - 99 years
All genders
Interventional
This study compares 2 combinations of drugs to prevent graft-versus-host disease (GVHD): Tacrolimus/methotrexate and Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best for future transplant patients. The purpose of its companion …
99 years or below
All genders
Phase 1
Amphivena Therapeutics, Inc. (Amphivena) is studying an investigational drug called AMV564, which may help to treat acute myeloid leukemia (AML). The purpose of this clinical research study is to find the highest tolerable dose that can be given to patients with AML, and to recommend a dose to be used …
99 years or below
All genders
Phase 1
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
18 years - 39 years
All genders
Phase 3
Interventional
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
 Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)
18 years - 65 years
All genders
Phase 1
Interventional
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
 Phase I Trial of Programmed Allogeneic CRISPR-edited T cells (PACE) Gene Edited to Eliminate Endogenous TCR  HLA-class I and HLA-class II and Engineered to Express anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients with Relapsed Or Refractory CD19+ Leukemia and Lymphoma
18 years - 99 years
All genders
Phase 1
Interventional
This research study is being conducted to evaluate an experimental drug called PACE CART19 in patients with leukemia or lymphoma. PACE CART19 consists of cells from a healthy donor that are genetically modified and designed to target your cancer.
18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
 UPCC 04717: Phase I  open label  dose-escalation study to evaluate the safety  expansion  persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor)  administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
99 years or below
All genders
Phase 1
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
 A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
18 years - 99 years
All genders
Phase 1
Interventional
This study is being done to determine what effects the therapy venetoclax has on acute lymphoblastic leukemia (ALL).This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed ALL.
18 years - 99 years
All genders
Phase 2
Please refer to Section 2 of the full protocol (Study Objectives). Please refer to Section 8.1 of the full protocol (Study Endpoints). Please refer to Section 8.1 of the full protocol (Study Endpoints).
21 - 30 of 35